相似文献
1
T-cell therapy at the threshold.
Nat Biotechnol. 2012 Jul 10;30(7):611-4. doi: 10.1038/nbt.2305.
2
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Cells. 2020 Jun 18;9(6):1485. doi: 10.3390/cells9061485.
3
Harnessing autophagy for adoptive T-cell therapy.
Immunotherapy. 2012 Jan;4(1):1-4. doi: 10.2217/imt.11.144.
4
Combining chemotherapy with CAR-T cell therapy in treating solid tumors.
Front Immunol. 2023 Mar 6;14:1140541. doi: 10.3389/fimmu.2023.1140541. eCollection 2023.
5
The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
Semin Cancer Biol. 2017 Aug;45:23-35. doi: 10.1016/j.semcancer.2017.02.010. Epub 2017 Feb 28.
6
How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?
Cancer J. 2021;27(2):134-142. doi: 10.1097/PPO.0000000000000516.
7
Nanomaterials for T-cell cancer immunotherapy.
Nat Nanotechnol. 2021 Jan;16(1):25-36. doi: 10.1038/s41565-020-00822-y. Epub 2021 Jan 12.
8
Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing.
Cells. 2022 Jan 13;11(2):269. doi: 10.3390/cells11020269.
9
Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
Cancer J. 2023;29(1):28-33. doi: 10.1097/PPO.0000000000000636.
10
Adoptive T-Cell Therapy for Solid Tumors.
Am Soc Clin Oncol Educ Book. 2017;37:193-204. doi: 10.1200/EDBK_180328.
引用本文的文献
1
Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice.
J Clin Invest. 2025 Apr 15;135(8). doi: 10.1172/JCI179014.
2
Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy.
J Nanobiotechnology. 2025 Mar 3;23(1):161. doi: 10.1186/s12951-025-03236-x.
3
Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment.
Front Immunol. 2024 Oct 8;15:1487782. doi: 10.3389/fimmu.2024.1487782. eCollection 2024.
4
Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review.
Investig Clin Urol. 2022 Sep;63(5):486-498. doi: 10.4111/icu.20220103.
5
The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy.
Acta Pharm Sin B. 2020 Nov;10(11):2156-2170. doi: 10.1016/j.apsb.2020.04.004. Epub 2020 Apr 19.
6
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors.
Front Oncol. 2020 Sep 23;10:565857. doi: 10.3389/fonc.2020.565857. eCollection 2020.
7
Delivering safer immunotherapies for cancer.
Adv Drug Deliv Rev. 2017 May 15;114:79-101. doi: 10.1016/j.addr.2017.05.011. Epub 2017 May 22.
8
Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.
J Infect Dis. 2017 Mar 15;215(suppl_3):S160-S171. doi: 10.1093/infdis/jix002.
9
Next frontiers in CAR T-cell therapy.
Mol Ther Oncolytics. 2016 Nov 30;3:16028. doi: 10.1038/mto.2016.28. eCollection 2016.
10
T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.
Cancer Cell. 2015 Nov 9;28(5):638-652. doi: 10.1016/j.ccell.2015.09.022. Epub 2015 Oct 29.
本文引用的文献
1
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
J Clin Oncol. 2011 Mar 1;29(7):917-24. doi: 10.1200/JCO.2010.32.2537. Epub 2011 Jan 31.
2
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28.
3
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
J Immunother. 2009 Feb-Mar;32(2):169-80. doi: 10.1097/CJI.0b013e318194a6e8.
Zotero 插件